Open to all faculty at the rank of assistant, associate, and full professor at HMS, its affiliated institutions, and the Harvard School of Dental Medicine, the awards provide critical funding to researchers who’ve made fundamental discoveries with the potential for becoming powerful clinical interventions.
“We’re living in a prolific time of scientific discovery, and it is our imperative to accelerate the pace of therapeutics research within the HMS community and translate more of our discoveries into new medicines,” said George Q. Daley, dean of HMS.
“The journey from molecule to medicine is long and often requires coordination across several institutions and organizations,” he added. “This critical funding helps us toward our goal.”
Now in its fifth and concluding year, the Blavatnik Therapeutics Challenge Awards have supported 20 research projects. Of the 17 projects awarded in the first 4 years of the program, four have already progressed to either the founding of a new company or licensing of the technology as part of a start-up. Two additional projects may enter clinical trials within the next year.
Full story: Blavatnik Therapeutics Challenge Awards Fuel Translational Research | Harvard Medical School
